Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CMLpatients receiving 600 mg/day of imatinib as initial therapy

T.P. Hughes, S. Branford, D.L. White, J. Reynolds, R. Koelmeyer, J.F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, J. Cooney, M.F. Leahy, P. Rowlings, J. Catalano, M. Hertzberg, R. Filshie, A.K. Mills, K. Fay, S. Durrant, H. JanuszewiczDavid Joske, C. Underhill, S. Dunkley, K. Lynch, A. Grigg

    Research output: Contribution to journalArticle

    136 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)3965-3973
    JournalBlood
    Volume112
    Issue number10
    DOIs
    Publication statusPublished - 2008

    Cite this

    Hughes, T. P., Branford, S., White, D. L., Reynolds, J., Koelmeyer, R., Seymour, J. F., Taylor, K., Arthur, C., Schwarer, A., Morton, J., Cooney, J., Leahy, M. F., Rowlings, P., Catalano, J., Hertzberg, M., Filshie, R., Mills, A. K., Fay, K., Durrant, S., ... Grigg, A. (2008). Impact of early dose intensity on cytogenetic and molecular responses in chronicphase CMLpatients receiving 600 mg/day of imatinib as initial therapy. Blood, 112(10), 3965-3973. https://doi.org/10.1182/blood-2008-06-161737